Advertisement
U.S. markets open in 6 minutes

Telesis Bio, Inc. (TBIO)

NasdaqGS - NasdaqGS Delayed Price. Currency in USD
0.4500+0.0150 (+3.45%)
At close: 04:00PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Price Crosses Moving Average

Price Crosses Moving Average

Previous Close0.4350
Open0.4388
Bid0.4250 x 100
Ask0.4499 x 100
Day's Range0.4282 - 0.4500
52 Week Range0.3000 - 3.3200
Volume78,918
Avg. Volume788,004
Market Cap13.493M
Beta (5Y Monthly)1.98
PE Ratio (TTM)N/A
EPS (TTM)-1.3100
Earnings DateMar 28, 2024 - Apr 01, 2024
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued

Subscribe to Yahoo Finance Plus to view Fair Value for TBIO

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Telesis Bio, Inc.
    VIR: What does Argus have to say about VIR?VIR BIOTECHNOLOGY INC has an Investment Rating of SELL; a target price of $8.000000; an Industry Subrating of Low; a Management Subrating of Low; a Safety Subrating of Low; a Financial Strength Subrating of Medium; a Growth Subrating of Medium; and a Value Subrating of High.
    Rating
    Fair Value
    Economic Moat
    yesterdayArgus Research
View more
  • GlobeNewswire

    Telesis Bio Announces Select Preliminary Fourth Quarter 2023 Financial Results

    Telesis Bio announces Q4 and full-year 2023 select preliminary financial results, highlighting strong BioXp kit sales, expanding gross margin and reduced expenseSAN DIEGO, Feb. 26, 2024 (GLOBE NEWSWIRE) -- Telesis Bio Inc. (NASDAQ: TBIO), a leading provider of RNA and DNA solutions enabling researchers to accelerate therapeutic discovery through advanced, flexible and rapid automated synthesis in their own lab, today announced certain preliminary, unaudited financial results for the fourth quart

  • GlobeNewswire

    Telesis Bio Reports Third Quarter 2023 Financial Results

    SAN DIEGO, Nov. 13, 2023 (GLOBE NEWSWIRE) -- Telesis Bio Inc. (NASDAQ: TBIO), a leader in automated multi-omic and synthetic biology solutions, today reported financial results for the third quarter of 2023. “This quarter, we continued to drive adoption of our instruments and kits, make progress against important collaborations, advance our mRNA strategy, and strengthen both our Board of Directors and Management Team,” said Todd R. Nelson, PhD, CEO, and founder of Telesis Bio. Highlights Strengt

  • GlobeNewswire

    Telesis Bio to Report Third Quarter Financial Results on Monday, November 13, 2023

    SAN DIEGO, Nov. 07, 2023 (GLOBE NEWSWIRE) -- Telesis Bio (Nasdaq: TBIO), a leader in automated multi-omic and synthetic biology solutions, today announced that it will release its third quarter 2023 financial results on Monday, November 13, 2023, after the market closes. The press release can be accessed via the Investor section of Telesis Bio’s website at https://ir.telesisbio.com/. About Telesis BioTelesis Bio is empowering scientists with the ability to create novel, synthetic biology-enabled